Jump to ContentJump to Main Navigation
Show Summary Details
More options …

The B.E. Journal of Economic Analysis & Policy

Editor-in-Chief: Jürges, Hendrik / Ludwig, Sandra

Ed. by Auriol , Emmanuelle / Brunner, Johann / Fleck, Robert / Mendola, Mariapia / Requate, Till / Schirle, Tammy / de Vries, Frans / Zulehner, Christine

4 Issues per year


IMPACT FACTOR 2016: 0.252
5-year IMPACT FACTOR: 0.755

CiteScore 2016: 0.48

SCImago Journal Rank (SJR) 2016: 0.330
Source Normalized Impact per Paper (SNIP) 2016: 0.526

Online
ISSN
1935-1682
See all formats and pricing
More options …
Volume 18, Issue 2

Issues

Volume 6 (2006)

Volume 4 (2004)

Volume 2 (2002)

Volume 1 (2001)

Corruption and Medicine Quality in Latin America: A Pilot Study

Roger Bate
  • American Enterprise Institute, 1789 Massachusetts Ave NW, Washington, DC 20036, United States of America
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Aparna Mathur
  • Corresponding author
  • American Enterprise Institute, 1789 Massachusetts Ave NW, Washington, DC 20036, United States of America
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2018-02-13 | DOI: https://doi.org/10.1515/bejeap-2017-0076

Abstract

Fake and substandard medicines are a significant problem in developing nations, and a growing problem in developed ones too. There have been assessments of basic medicine quality from many countries and regions across the world but almost none in Central and South America. Over the past decade, as part of our research, we have collected over ten thousand samples of medicines from 22 cities in emerging markets, but the only one from the Latin region was Sao Paolo in Brazil. We have now rectified this gap, at least for one critical medicine, the broad spectrum antibiotic ciprofloxacin. Using original, self-collected data from ten countries in Latin America, we test whether the 687 Ciprofloxacin treatments pass the Global Pharma Health Fund e.V. Minilab® protocol to identify substandard or counterfeit medicines. In terms of quality, 93 percent of drugs were good quality. Within the drugs that failed the quality test, the majority were substandard rather than fake. About 26 % of the poor quality drugs were fake, with zero active pharmaceutical ingredient (API), while the rest were substandard, with less than 80 % API. In line with results from our earlier studies, we find that products that were locally registered, as well as those with SRA or WHO pre-qualification, were more likely to pass the test. A new finding in this paper is that corruption is a key predictor of poor quality drugs. Less corrupt countries had higher levels of passing drugs.

Keywords: drug quality; corruption; Latin America

References

  • Afzar, O., and T. Gurgur. 2008. “Does Corruption Affect Health and Education Outcomes in the Philippines?” Economics of Governance 9(3):197–244.CrossrefGoogle Scholar

  • Akunyili, D. (2006). The Fight against Counterfeit Drugs in Nigeria. In Transparency International, Global Corruption Report 2006.Google Scholar

  • Attaran, A., D. Barry, S. Basheer, R. Bate, D. Benton, J. Chauvin, and M. McKee. 2012. “How to Achieve International Action on Falsified and Substandard Medicines.” British Medical Journal 345:e7381.Web of ScienceGoogle Scholar

  • Bate, R. 2012. Phake: The Deadly World of Falsified and Substandard Medicines. Washington, DC: AEI Press.Google Scholar

  • Bate, R., G.Z. Jin, and A. Mathur (2012). Counterfeit or Substandard? Assessing Price and Non- Price Signals of Drug Quality. (NBER Working Paper No. 18073). Cambridge, MA: National Bureau of Economic Research.Google Scholar

  • Bate, R., G.Z. Jin, and A. Mathur. 2015. “Falsified or Substandard? Assessing Price and Non-Price Signals of Drug Quality.” Journal of Economics and Management Strategy 24 (24): 687–711.Web of ScienceCrossrefGoogle Scholar

  • Bate, R., G.Z. Jin, A. Mathur, and A. Attaran. 2016. “Poor-Quality Drugs and Global Trade: A Pilot Study.” American Journal of Heath Economics 2(3):373–398.CrossrefGoogle Scholar

  • Bate, R., L. Mooney, and K. Hess. 2010. “Medicine Registration and Medicine Quality: A Preliminary Analysis of Key Cities in Emerging Markets.” Research and Reports in Tropical Medicine 1:89–93.Google Scholar

  • Bate, R., E. Putze, S. Naoshy, A. McPherson, and L. Mooney (2010). Drug Registration - a Necessary but Not Sufficient Condition for Good Quality Drugs – A Preliminary Analysis of 12 Countries. (Working Paper). Congella, South Africa: Africa Fighting Malaria.Google Scholar

  • Caudron, J.M., N. Ford, M. Henkens, C. Mace, R. Kiddle-Monroe, and J. Pin. 2008. “Substandard Medicines in Resource-Poor Settings: A Problem that Can No Longer Be Ignored.” Tropical Medicine & International Health 13 (8): 1062–1072.CrossrefWeb of ScienceGoogle Scholar

  • Cockburn, R., P.N. Newton, E.K. Agyarko, D. Akunyili, and N.J. White. 2005. “The Global Threat of Counterfeit Drugs: Why Industry and Governments Must Communicate the Dangers.” Plos Med 2 (4): 302–308.Web of ScienceGoogle Scholar

  • Cohen, J.C. 2005. Pharmaceuticals and Corruption: A Risk Assessment. Washington, DC: World Bank.Google Scholar

  • Davoodi, H., S. Gupta, and E. Tiongson (2000). Corruption and the Provision of Health Care and Education Services. (IMF Working Paper No. 00/116). Washington, DC: International Monetary Fund.Google Scholar

  • Echeverría, J.F. 2016. Mejores Ciudades Para Hacer Negocios 2016. Coral Gables, FL: América Economía.Google Scholar

  • Global Health Intelligence (2016). Opportunities in Latin America’s Healthcare Sector: Looking Ahead to 2016. Retrieved from http://globalhealthintelligence.com/opportunities-in-latin-americas-healthcare-sector-2016/.

  • Hunt, J. (2007). Bribery in Health Care in Peru and Uganda. (NBER Working Paper No. 13034). Cambridge, MA: National Bureau of Economic Research.Google Scholar

  • Institute of Medicine. 2013. Countering the Problem of Falsified and Substandard Drugs. Washington, DC: National Academy of Sciences.Google Scholar

  • Jähnke, R.W.O., G. Küsters, and K. Fleischer. 2001. “Low-Cost Quality Assurance of Medicines Using the GPHF-Minilab.” Drug Information Journal 35: 941–945.CrossrefGoogle Scholar

  • Kohler, J.C., N. Mitsakakis, F. Saadat, D. Bynh, and M.G. Martinez. 2015. “Does Pharmaceutical Pricing Transparency Matter? Examining Brazil’s Public Procurement System.” Globalization and Health 11 (34): 1–13.Web of ScienceGoogle Scholar

  • Lewis, M. (2006) Governance and Corruption in Public Health Care Systems, Working Paper, Center for Global Development; Washington DCGoogle Scholar

  • Mackey, T.K., B.A. Liang, P. York, and T. Kubic. 2015. “Counterfeit Drug Penetration into Global Legitimate Medicine Supply Chains: A Global Assessment.” American Journal of Tropical Medicine and Hygiene 92(Suppl 6):59–67.Web of ScienceCrossrefGoogle Scholar

  • Martin, A., and J.P. Spinetto. 2016. Can Paraguay Escape Decades of Despotism, Decades of Despotism, Ineptitude, and Ineptitude, and Corruption? Bloomberg, March 22. http://www.bloomberg.com/features/2016-paraguay-president-horacio-cartes/.

  • Morris, J., and P. Stevens. 2006. Counterfeit Medicines in Less Developed Countries. London: International Policy NetworkGoogle Scholar

  • Oxfam. (2011). Oxfam Annual Report 2010-2011. Oxford, United Kingdom.Google Scholar

  • Pugatch, M., D. Tortensson, and M. Laufer. 2015. The Next Frontier in Ensuring the Quality of Medicines. District of Columbia: Pugatch ConsiliumGoogle Scholar

  • Rose, R. (2006). Corruption Is Bad for Your Health: Findings from Central and Eastern Europe. In Transparency International, Global Corruption Report 2006.Google Scholar

  • Rose-Ackerman, S. (2015). Corruption in the Procurement of Pharmaceuticals and Medical Equipment in China: The Incentives Facing Multinationals, Domestic Firms and Hospital Officials. Yale Faculty Scholarship Series. Paper 4945.Google Scholar

  • Savedoff, W. (2007). Transparency and Corruption in the Health Sector: A Conceptual Framework and Ideas for Action in Latin American and the Caribbean. Sustainable Development Department, Inter-American Development Bank, Health Technical Note 03/2007.Google Scholar

  • Schargrodsky, E., J. Mera, and F. Weinschelbaum.2001. “Transparency and Accountability in Argentina’s Hospitals.” In Diagnosis Corruption: Fraud in Latin American Public Hospitals edited by R. Di Tella and W. Savedoff. Washington, DC: Inter-American Development Bank.Google Scholar

  • Tortensson, D., and M. Pugatch. 2010. What Lies Within?: Procurement Processes and the Risk of Substandard Medicines. Stockholm, Sweden: Stockholm NetworkGoogle Scholar

  • Transparency International. 2006. Global Corruption Report: Corruption in Health Berlin Germany: Transparency InternationalGoogle Scholar

  • Transparency International. 2015. Corruption Perceptions Index 2015 Berlin, Germany: Transparency InternationalGoogle Scholar

  • U.S. Trade Representative. (2016). Special 301 Report. Washington, DC: Office of the United States Trade Representative.Google Scholar

  • Vian, T. (2002). Corruption and the Health Care Sector: Sectoral Perspectives on Corruption. USAID, Washington, DC i-34.Google Scholar

  • Vian, T. 2008. “Review of Corruption in the Health Sector: Theory, Methods and Interventions.” Health Policy and Planning 23 (2): 83–94.Web of ScienceGoogle Scholar

  • Webster, P.C. 2012. “Health in Colombia: A System in Crisis.” Canadian Medical Association Journal 184(6):E289–E290.Web of ScienceGoogle Scholar

  • Wells, M. (2013, June 24). Criminals Flooding Paraguay with Counterfeit Drugs. InSight Crime. Retrieved from http://www.insightcrime.org/news-briefs/criminals-killing-paraguayans-with-counterfeit-drugs.

  • World Bank. xxxx. Poverty Net Tool and Practices Washington, DC: World BankGoogle Scholar

  • World Bank. xxxx. Logistics Performance Index 2016. Data File Washington, DC: World BankGoogle Scholar

About the article

Published Online: 2018-02-13


The funding for data collection and testing was made by two main sources, Legatum Institute and Reason Foundation.


Citation Information: The B.E. Journal of Economic Analysis & Policy, Volume 18, Issue 2, 20170076, ISSN (Online) 1935-1682, DOI: https://doi.org/10.1515/bejeap-2017-0076.

Export Citation

© 2018 Walter de Gruyter GmbH, Berlin/Boston. Copyright Clearance Center

Comments (0)

Please log in or register to comment.
Log in